Sarfez Pharmaceuticals

Open enrollment with a later-stage pipeline tilt

According to ClinicalTrials.gov-derived indexes, Sarfez Pharmaceuticals sits in the upper quartile of US sponsors by registered trial count (#2,085 of 15,742 sponsors by registered trial count).

6 total trials 1 currently recruiting 5 completed later-stage tilt upper quartile by trial count

Sarfez Pharmaceuticals: 6 sponsored US clinical trials, 1 recruiting.

Sarfez Pharmaceuticals sponsors 6 registered US clinical trials on ClinicalTrials.gov, 1 of them currently recruiting, and 5 completed. 5 of these trials are in Phase 3-4 (later-stage) and 1 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Bioavailability Heathy Volunteers, with 1 trials.

Upper-quartile sponsor footprint

Sarfez Pharmaceuticals sits in the upper quartile of the sponsor corpus (#2,085 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.

Open and recent trials

6 total, page 1 of 1

RECRUITING Phase 3

A Study Comparing the Clinical Benefit of Finerenone Versus a Fixed Dose Combination (FDC) of Extended-Release Torsemide and Spironolactone in Patients With Hypertension and Chronic Kidney Disease

NCT07223502
COMPLETED Phase 3

Bioavailability and Bioequivalence Study of ER Torsemide and Spironolactone FDC Tablet in Healthy Subjects

NCT07015671
COMPLETED Phase 3

A Study to Evaluate the Effect of Food or no Food on the Bioavailability of an Extended Release (ER) Torsemide and Spironolactone Fixed Dose Combination (FDC) Tablet in Healthy Adult Subjects

NCT07043634
COMPLETED Phase 3

Bioavailability and Bioequivalence Study of Extended Release Torsemide and Spironolactone

NCT07046975
COMPLETED Phase 4

Comparing Natriuretic Effects of ER Torsemide to IR Torsemide in Patients With Heart Failure

NCT06995144
COMPLETED Phase 2

Effect of Extended Release Torsemide in Patients With Congestive Heart Failure and Overactive Bladder

NCT06206512

Phase Distribution

PhaseTrial count
Phase 2 1
Phase 3 4
Phase 4 1

Therapeutic Areas

Bioavailability Heathy Volunteers 1
Pulmonary Congestion 1
Hypertension (HTN) 1
Fluid Overload 1
Edema 1
Heart Failure 1

Where Sarfez Pharmaceuticals enrollment is open (later-stage tilt)

1 recruiting of 6 indexed (17% open); 5 completed (83%).

Phase mix: 5 late (III/IV) vs 1 early (I/II) (later-stage heavy).

Top condition: Bioavailability Heathy Volunteers (1 trial), 5 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

Sarfez Pharmaceuticals: open-pipeline peers nationwide

Peers matched on 6 registered trials and 17% open enrollment, not the therapeutic-area sidebar.

Sarfez Pharmaceuticals sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 468101214 0%20%40%60%80% Total trials Recruiting share Sarfez Pharmaceuticals23andMeAardvark TherapeuticsAbbisko Therapeutics CoAbGenomics B.V Taiwan BranchAdageneAgendiaAkamis BioAngiodynamics
Sarfez Pharmaceuticals sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Sarfez Pharmaceuticals sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 6 trials (± recruiting share)

Sponsors near 17% open enrollment (± trial volume)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this Sarfez Pharmaceuticals page

6 registered trials is a research-attention snapshot, not an endorsement of Sarfez Pharmaceuticals or any single study.

  • 1 of Sarfez Pharmaceuticals's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Bioavailability Heathy Volunteers is the condition Sarfez Pharmaceuticals studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Bioavailability Heathy Volunteers trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Sarfez Pharmaceuticals pipeline card: 6 registered trials from official public datasets.Report a data error.